Event Highlights Routine Use of The NephroCheck ® Test For AKI Risk Assessment

Millions of hospitalised patients are affected by acute kidney injury (AKI) globally each year, making this a significant health threat. 

An educational symposium being held on Wednesday, March 19, 2014 at 12:30 local time during the 34th International Symposium on Intensive Care and Emergency Medicine (ISICEM) in Brussels, Belgium, will feature leading critical care experts discussing every day use of novel biomarkers for assessing risk of AKI in the critically ill patient.

Astute Medical, Inc. is sponsoring the event entitled "New AKI biomarkers: How to use them in everyday clinical routine." 

Conference attendees can register for the event at AKIAssessment.com. Event participants and others can follow the live event via Twitter @ACuteKidneyMan.

With its link to increased mortality and morbidity, longer intensive care unit stays, and higher in-hospital cost, AKI is a significant public hazard and its incidence (2.1/1000 population) is similar to that of acute myocardial infarction, or heart attack.

In a recent article, published in the Clinical Journal of the American Society of Nephrology, the suggestion was made that AKI could be more deadly than heart attack. In contrast to heart attack however, AKI is asymptomatic lacking warning signs such as shortness of breath, pain, or other clinical symptoms, especially in the early stages when intervention is most beneficial.

Program highlights include:
  • Dr. Rinaldo Bellomo of Monash University in Australia, who will moderate the session,
  • Dr. Lui Forni of Worthing Hospital in the United Kingdom, who will discuss the role of biomarkers of cell cycle arrest in regards to AKI, and
  • Dr. Ivan Gocze of University Hospital Regensburg, Dr. Alex Zarbock of the University of Muenster, and Dr. Christophe Vinsonneau of Paris Descartes University, who will each present case studies describing the utilisation of new AKI biomarkers in everyday routine.
  • Astute Medical, Inc., has developed the CE-marked NephroCheck® Test to facilitate the early assessment of moderate or severe AKI risk in the critically ill. The NephroCheck® Test and the Astute140® Meter are on the European market and not available in the United States.

The test utilises fluorescence immunoassay technology to detect and measure two biomarkers of AKI, tissue inhibitor of metalloproteinase 2 (TIMP-2) and insulin-like growth factor binding protein 7(IGFBP-7) in human urine. The release of TIMP-2 and IGFBP-7 by kidney cells acts as a biological alarm signaling that the cells are acutely stressed and the kidney is at risk for AKI, which can cause permanent damage and loss of function.

The recently published Kidney Disease Improving Global Outcomes (KDIGO) Guideline for AKI recommends prompt evaluation of patients along with the implementation of kidney-sparing interventions for patients determined to be at risk and thus vulnerable to permanent damage from unchecked AKI.

Astute Medical, Inc. is an exhibitor at the ISICEM meeting, the largest and most prestigious critical care medicine conference in the world, attracting approximately 6,000 key opinion leaders, physicians, and other healthcare personnel each year. Plan to visit Astute Medical's booth located at Stand 2.66-2.68 in the main exhibit hall.

18 March 2014

«« Study: Decrease in Risk of Death Among ICU Patients With Severe Sepsis

ISICEM 2014: B. Braun Satellite Symposium »»

Latest Articles

ISICEM, AKI, kidney, Risk, AstuteMedical, kidney failure, Critical Care, ISICEM 2014 Event Highlights Routine Use of The NephroCheck ® Test For AKI Risk Assessment Millions of hospitalised patients are affected by acute kidney injury (A...